EHR patient recruitment could improve clinical trial matching, but workflow integration, data quality, interoperability, and AI validation remain key challenges.
EHR patient recruitment could help clinical trial teams identify eligible participants faster by turning routinely collected health data into recruitment intelligence.
However, the technology still faces significant challenges around workflow integration, data quality, interoperability, and meaningful evaluation.
Image
Why EHR Data Could Transform Trial Recruitment
Recruitment remains one of the most persistent operational challenges in clinical development.
Finding patients who meet complex inclusion and exclusion criteria requires significant investigator and research-coordinator time, while manual screening can miss potential participants.
Electronic health records (EHRs) contain a continually updated picture of a patient's disease status, treatments, clinical measurements, and, in some settings, genomic information.
This could make them a potentially valuable source for automated or semi-automated patient-trial matching.
The technology is generally described as a Clinical Trial Recruitment Support System (CTRSS). These systems analyse patient information against trial eligibility criteria and can identify people who may warrant further assessment.
The concept is not new. Routine clinical data does help support recruitment and reduce administrative work in some studies already, where it identifies additional potential participants beyond manual recruitment and substantially reduces the time required for some data-entry activities.
The opportunity now is to make these systems more scalable, integrated, and useful within everyday clinical workflows.
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Image
EHR Supported Clinical Trial Patient Recruitment
A newscoping review examined published evaluations of EHR-based CTRSS between 2013 and 2024.
75% of systems were trial-centred rather than patient-centred.
Only 20% provided eligibility information at clinically relevant points in the patient's journey.
Just 9% actively notified targeted users about potential matches.
32% transformed EHR data using standard data models.
48% used computer assistance to transform eligibility criteria.
55% relied on structured-data queries for patient-trial matching.
61% of evaluations were retrospective.
Only 23% assessed the complete pathway from data transformation through to patient-trial matching.
These figures reveal an important gap in that having an algorithm that can identify a possible match is not the same as embedding recruitment intelligence into clinical care.
Image
EHR Patient Recruitment Needs More Than Matching
Clinical workflow, rather than technology, is arguably the most important factor.
Many systems remain designed around the trial itself. They identify potential participants but do not necessarily support the wider collaboration between patients, clinicians, research teams, and study coordinators.
That matters because recruitment is a process, not a single algorithmic event.
A useful system needs to surface relevant information at the right point, to the right person, with enough context to support a decision.
Earlier research into EHR recruitment systems similarly found that standard EHR environments could provide useful query, workflow, reporting, and notification capabilities, but often lacks dedicated structures for managing recruitment and trial information.
Embedding recruitment intelligence, therefore, rather than another standalone screening application, might be a better way to go with EHR support of patient recruitment.
Data Quality Decides Patient Recruitment Success
Automation cannot compensate for incomplete or poorly structured clinical data.
EHR information is collected primarily to support patient care, not research.
Different systems can record the same clinical concept in different ways. Important information may also sit within unstructured clinical notes rather than standardised fields.
Only 32% of evaluated systems reported transforming EHR data according to standard models, highlighting the continuing importance of interoperability and data harmonisation.
Eligibility criteria create another challenge. Trial protocols are written for human interpretation, while software requires criteria that can be represented computationally.
Natural language processing, machine learning, structured queries, and other approaches can help bridge that gap. However, the scoping review found that eligibility-criteria transformation was computer-assisted in fewer than half of the evaluated systems.
This means data infrastructure should be part of recruitment strategy.
Proving the Impact of EHR Supported Patient Recruitment
EHR-based recruitment systems can work but need stronger, more consistent evaluation.
Future systems need to demonstrate whether they improve recruitment rates, reduce delays, lower costs, support clinicians, and improve patient inclusion.
These EHR technology should be assessed across user, technology, and societal dimensions, rather than assessing only whether an algorithm will produce technically accurate matches.
That’s important for sponsors because a highly accurate matching engine has limited value if clinicians ignore its alerts, patients cannot easily act on them, or the underlying data cannot support reliable eligibility decisions.
The strategic opportunity is broader than automated prescreening.
EHR patient recruitment could become part of a connected clinical trial intelligence layer, linking protocol criteria, patient data, investigator workflows, and research operations.
At Pharmatica, we track the technologies reshaping Clinical Development, from digital recruitment to real-world data and AI-enabled trial infrastructure. Our focus is where technology meets operational reality, helping decision-makers understand what is ready to scale, what still needs validation, and where the next gains in Clinical Development may emerge.
Pharmatica: Insight. Connection. Impact.
Image
Frequently Asked Questions
What is EHR patient recruitment?
EHR patient recruitment uses electronic health record data to identify patients who may meet the eligibility criteria for a clinical trial.
How do EHR recruitment systems identify clinical trial patients?
Clinical Trial Recruitment Support Systems compare patient data with predefined trial eligibility criteria using approaches such as structured queries, natural language processing, and machine learning.
What are the benefits of EHR-based clinical trial recruitment?
EHR-based recruitment can reduce manual screening, identify potential participants more efficiently, and provide recruitment information using routinely collected clinical data.
What are the challenges of EHR patient recruitment?
Key challenges for EHR patient recruitment include data quality, interoperability, eligibility-criteria processing, workflow integration, clinician acceptance, and consistent evaluation.
Can AI improve EHR patient recruitment?
AI can support the processing of unstructured EHR information and complex eligibility criteria. However, the latest evidence shows that technical performance alone is insufficient. Successful systems also need strong clinical workflow integration and trustworthy data.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
3
Why not support
Nicole Dale
by giving this content a like
CMS Finalises Medicare GLOBE to Rewrite Drug Pricing
The Medicare GLOBE drug payment uses international drug prices to reshape selected Medicare Part B rebates. Here is what the final CMS rule means for pharma.
Where Healthcare AI Investment Is Going — And Where It Isn't
The data is out: Two-thirds of AI healthcare startup investment went to just three domains. Insight into clinical leadership, gender inclusivity, and geographical access reveals a sector building for investability… not clinical need.
The AI Bioweapons Risk: We Cannot Afford to Look Away
The risk of AI being used to create a bioweapon is a serious concern for pharma biosecurity after researchers found AI-designed toxins can evade DNA screening. Here’s what you need to know about the AI and bioweapons risk.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Can Large Language Models Solve More Rare Disease Genomes?
LLM-assisted rare disease re-assessment improves genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.
Comments (0)